|
Date
|
Title
|
Speaker
|
28/05/2019
|
Use of orthoxenografts and tumoroids models to unravel the resistance mechanisms in unstable colorectal cancer
|
Juan Francisco Martín Tejera
|
16/04/2019
|
Extraordinary Seminar: Histopathological growth patterns of liver metastases: Clinical impact and biology
|
Peter Vermeulen
|
12/03/2019
|
SAMHD1 and Cancer
|
Eudald Felip
|
19/02/2019
|
Novel Markets and Targets of Collective Cell Invasion Before and After Anti-angiogenic Therapies
|
Julia Sllaberry
|
6/11/2018
|
Deciphering the metabolo-epigenetic activities of metformin
|
Elisabet Cuyàs
|
25/09/2018
|
A synthetic lethal CRISPR/Cas9 screen for castration resistant prostate cancer
|
Adrián Tébar
| 09/07/2018
|
Extraordinary Seminar: Identifying gene regulatory variants and GxE interactions for molecular and organismal traits
|
Roger Pique-Reig
|
04/07//2018
|
Extraordinary Seminar: Redox regulation of tumor microenvironment in triple negative breast cancer
|
Chiara Gorrini
|
3/07/2018
|
Therapeutic properties of E1a
|
Francisco José Cimas
|
19/06/2018
|
Adaptation to genomic instability, increase in oxidative metabolism?
|
Alvaro Lahiguera Belenguer
|
11/06/2018
|
Extraordinary Seminar: Computational Genomics in Biomedicine
|
David Torrents
|
5/06/2018
|
Role of CXCR2 pathway on taxane-acquired resistance and platinum sensitivity in metastatic prostate cancer cellular models
|
Vicençs Ruiz de Porras Fondevila
|
15/05/2018
|
Oncolytic Adenovirus expressing tumor neoepitopes as a vaccine
|
Martí Farrera
|
24/04/2018
|
Prognostic markers and therapeutic targets for metastatic Renal Cell Carcinoma
|
Mariona Bartroli Comellas
|
10/04/2018
|
Extraordinary Seminar: miR-424/503: the discovery of a new tumor suppressor gene
|
David Llobet Navas
|
21/03/2018
|
Extraordinary Seminar: Old challenges and new solutions unveiling intratumor heterogeneity
|
José Ignacio López Fernández de Villaverde
|
|
08/03/2018
|
Extraordinary Seminar: Breast tumor heterogeneity, resistance and metastasis
|
Mohamed Bentires-Alj
|
06/03/2018
|
PI3-kinase signalling regulates pericyte maturation during angiogenesis
|
Ana M. Figueiredo
|
|
20/02/2018
|
Serum biomarkers of lymphangioleiomyomatosis highlight novel therapeutic opportunities
|
Carmen Herranz
|
|
30/01/2018
|
Ongoing research projects in Malignant Pleural Mesothelioma. An update on the latest data
|
Elisabeth Aliagas
|
|
19/12/2017
|
Arming oncolytic adenovirus with FAP-targeting bispecific T-cell engager to improve antitumor efficacy
|
Jana de Sostoa
|
|
28/11/2017
|
CD44 involvement in tumor malignization induced by anti-angiogenic therapy in renal cell carcinoma
|
Jordi Sensarrich
|
|
26/09/2017
|
Tasting anti-cancer molecules in olive oil
|
Javier Menéndez
|
|
11/07/2017
|
Cancer modulators: a transversal ProCURE project
|
Luis Palomero
|
|
27/06/2017
|
PI3K signalling regulates cell rearrangements in angiogènesis
|
Ana Angulo
|
|
13/06/2017
|
Mechanisms of malignization after anti-VEGF therapies in renal cell carcinoma
|
Roser Pons
|
|
30/05/2017
|
A role for CXCR4 in hematogenous ovarian cancer dissemination
|
Agnès Figueras
|
|
16/05/2017
|
Human menstrual blood-derived mesenchymal stem cells as potencial cell carriers for oncolytic adenovirus
|
Rafael Moreno
|
|
02/05/2017
|
Epigenetic mechanisms and therapeutic opportunities metastatic castration resistent prostate cancer
|
Katia Ruggero
|
|
18/04/2017
|
PADI enzymes in skin and colorectal cancer
|
Neus Cantariño Iglesias
|
|
14/03/2017
|
Investigating the role of myeloid-derived HIF factors in retinal neovascularization
|
Pilar Villacampa Alcubierre
|
|
28/02/2017
|
Research lines in thoracic tumors
|
Ernest Nadal
|
|
07/02/2017
|
Stroma-mediated drug resistance in colorectal cancer
|
Samuel Gonçalves
|
|
24/01/2017
|
Translational study of lymphangioleiomyomatosis tissue origin, in vivo model and therapeutic strategies
|
Carmen Herranz
|
